Imaging observations of pulmonary inflammatory myofibroblastic tumors in patients over 40 years old

JIANG WU¹, HONG ZHU¹, KAI LI², CAI-YUN YUAN³, YAN-FEN WANG⁴ and GUANG-MING LU³

¹Department of Nuclear Medicine, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu 210002; ²Department of Pharmacology, Soochow University, Suzhou, Jiangsu 215123; Departments of ³Medical Imaging and ⁴Pathology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu 210002, P.R. China

Received April 16, 2014; Accepted January 16, 2015

DOI: 10.3892/ol.2015.2923

Abstract. Pulmonary inflammatory myofibroblastic tumors (PIMTs) are extremely rare in adults. If occurring in patients >40 years old, PIMT should be rapidly distinguished from lung cancer. The present study aimed to characterize the imaging features of PIMT in patients >40 years old in order to improve the diagnosis of PIMT. The imaging data of 10 patients with PIMT were reviewed retrospectively. Of the patients, eight underwent computed tomography (CT), two underwent positron emission tomography (PET)/CT and four underwent single-photon emission computed tomography (SPECT). Unenhanced CT revealed 10 lesions with a maximum diameter ranging between 5 and 57 mm located in the lower (n=6) or upper (n=4) lobe, in a peripheral (n=9) or central (n=1) region, and that were well- (n=4) or ill-defined (n=6), and round to oval (n=5) or irregular (n=5) in shape. Calcification (n=3), necrosis (n=6), cavity (n=4), air bronchogram (n=6) and obstructive pneumonia (n=1) were also observed in the patients. Contrast-enhanced CT revealed six lesions with moderate to high contrast enhancement in the arterial and venous phases, including four lesions with delayed enhancement. PET/CT identified two lesions with increased tracer uptake that were homogeneous and heterogeneous and each exhibited a maximal standard uptake value (SUVmax) of 6.0 and 5.4, respectively. The delayed PET/CT revealed foci that each exhibited an increased SUVmax of 6.9 and 5.9, respectively. SPECT demonstrated no definitive bone metastases, but did reveal atypical hypertrophic pulmonary osteoarthropathy in one patient. The combined imaging methods may lead to a more precise evaluation of PIMT in patients >40 years old.

Introducion

Inflammatory myofibroblastic tumor (IMT) is a rare disorder that was previously referred to by a variety of synonyms, including inflammatory pseudotumor, plasma cell granuloma, fibroxanthoma, fibrous histiocytoma and xanthogranuloma (1). In 2002, the World Health Organization classification scheme defined IMT as a 'distinctive lesion composed of myofibroblastic spindle cells accompanied by an inflammatory infiltrate of plasma cells, lymphocytes and eosinophils' (2). Despite its precise definition, IMT remains controversial in regard to its nature and origin. With alterations in the anaplastic lymphoma kinase (ALK) gene and an overexpression of ALK protein reported in many cases of IMT, the concept that IMT is a true neoplasm, rather than a reactive process, has been increasingly accepted (2-4). Furthermore, reported cases of IMTs exhibiting aggressive growth, local invasion, recurrence and even distant metastasis, also supports this concept (5-10).

IMT may occur at any age, but usually affects children and adults <40 years old (6,11). IMT primarily affects the lung, and accounts for 0.04-1% of all reported lung tumors (12,13). Pulmonary IMT (PIMT) is the most frequently diagnosed primary lung mass in children (14). Therefore, a large number of studies regarding childhood PIMT exist in the literature. For adults, particularly those >40 years old, a relatively small number of studies concerning PIMT have been published, due to its rarity. Furthermore, the most common malignant tumor of the lung, lung cancer, predominantly affects this age group. Therefore, it is of great importance to identify PIMT in patients over the age of 40.

PIMT is challenging to diagnose in the absence of any pathological evidence, as few of its clinical manifestations and laboratory results are specific. Imaging features of PIMT remain poorly recognized, although a number of radiological studies referring to chest X-ray, computed tomography (CT) and magnetic resonance imaging have been published (12,15,16). Recently, ¹⁸F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT has been widely used for the diagnosis and differential diagnosis of lung masses. Therefore, a requirement exists to extend the understanding of ¹⁸F-FDG PET/CT in PIMT. Additionally, single-photon emission computed tomography (SPECT) bone scans are
frequently performed during the staging of lung cancers, and also for the indirect confirmation of lung cancer that has metastasized to the bone. The present study retrospectively analyzed the CT, $^{18}$F-FDG PET/CT and SPECT bone scan findings of PIMT occurring in patients >40 years old.

**Patients and methods**

*Patient characteristics.* Between September 2004 and June 2013, 10 patients, consisting of eight males and two females aged between 41 and 65 years, with a mean age of 56 years, were pathologically diagnosed with PIMT following surgical resection or a biopsy at Jinling Hospital, School of Medicine, Nanjing University (Nanjing, China). Of the 10 patients, eight underwent CT and two underwent $^{18}$F-FDG PET/CT. In four of the 10 patients, a SPECT bone scan using $^{99}$mTc-methylene diphosphonate (MDP) was performed in order to determine the presence or absence of bone metastasis. The clinical data of the patients were retrospectively analyzed (Table I).

*CT examination.* Of the eight patients who underwent CT examination, seven underwent plain and contrast-enhanced chest CT images and one underwent non-enhanced CT images alone. The scans were performed using a dual-source CT (Somatom Definition; Siemens Healthcare, Malvern, PA, USA) and a double-slice spiral CT scanners (Somatom Spirit; Siemens Healthcare). The CT parameters were as follows: A tube voltage of 120 kVp, a tube current of 150 mAs, a reconstruction interval of 2 mm, a slice thickness of 2 mm, a field of view of 250-350 mm and a matrix size of 512x512. The contrast-enhanced CT scan was performed with an intravenous injection of 100 ml iopamidol or 80 ml omnipaque at a rate of 2.5 ml/s, administered by a high-pressure autoinjector. CT enhancement was obtained in the arterial and venous phases, 20 and 50 sec after the injection of the contrast agent, respectively. The chest CT images were evaluated by the consensus of two experienced radiologists for the location, shape, size, density, margin and contrast enhancement of the lesions.

$^{18}$F-FDG PET/CT imaging. The patients were asked to fast for at least 6 h prior to receiving an intravenous injection of ~370 MBq $^{18}$F-FDG. In addition, blood glucose was measured prior to the injection to ensure that levels were <140 mg/dl. The initial whole-body scan was carried out 60 min subsequent to the injection using a PET/CT system (Biography Sensation 16; Siemens Healthcare). The delayed scan was then localized to the lung and performed 120 min subsequent to the injection. The PET emission scan was performed with an acquisition time of 3 min for each bed. Next, PET data were obtained with the attenuation correction calculated from the coregistered CT images. Consequently, PET, CT and fused images of the early scan were displayed, in addition to those of the delayed imaging. The images were then visually interpreted by the consensus of two experienced nuclear medicine physicians for the location, shape, size, density, margin and $^{18}$F-FDG uptake pattern of the pulmonary lesions. The maximal standard uptake values (SUV$_\text{max}$) of the dual-time-point were also calculated.

SPECT bone scan. In four of the 10 patients, a SPECT bone scan (e.cam Signature Series; Siemens Healthcare) was performed 3 h subsequent to the intravenous administration of 1110 MBq $^{99}$mTc-MDP. Anterior and posterior whole body planar images were acquired in a continuous mode at a scan speed of 20 cm/min using parallel-hole, low-energy, high-resolution collimators, with the patient in the supine position. The matrix size was 256x1024, and the zoom was 1.0 during the total acquisition. The whole body planar images were visually assessed by two experienced nuclear medicine physicians for the presence or absence of bone metastasis.

**Results**

*CT findings.* The CT findings of PIMT in the present study were based on 10 patients, consisting of eight who underwent routine CT examination and two who underwent the unenhanced CT component of PET/CT (Table II). CT revealed 10 lesions, of which four were located in the upper lobe and six were located in the lower lobe (Fig. 1A). In total, three lesions were located in the left lung and seven involved the right lung. A central parenchymal lesion was only identified in one patient, but the presence of a peripheral parenchymal lesion was revealed in nine patients, of which six presented with a sub-pleural mass (Fig. 1B). The maximum diameters of the ten lesions, comprising eight masses and two nodules, ranged between 5 and 57 mm. The lesions were either well- (n=4; Fig. 2A) or ill-defined (n=6; Fig. 3A) and round to oval (n=5; Fig. 2A) or irregular (n=5; Fig. 4A and B) in shape. The associated CT findings demonstrated calcification (n=3), necrosis (n=6; Fig. 1C and D), cavity (n=4; Fig. 3A and B), air bronchogram (n=6; Fig. 4A and B) and obstructive pneumonia (n=1). In four of the six lesions with necrosis, peripheral necrosis was evident within the lesions (Fig. 1C and D).

In total, seven patients underwent contrast-enhanced CT, but one pulmonary lesion was unable to be evaluated by contrast enhancement due to a small maximum diameter of 5 mm (Fig. 2B and C). The degree of contrast enhancement was measured in six patients. The results revealed that lesions increased in attenuation by between 12 and 79.1 Hounsfield units (HU; mean, 38.5±22.8 HU) in the arterial phase, and between 30.4 and 57.9 HU (mean, 44.2±10.2 HU) in the venous phase (Fig. 3C and D).

$^{18}$F-FDG PET/CT findings. In total, two patients with PIMT underwent $^{18}$F-FDG PET/CT imaging. In one patient, a mass-like high FDG uptake was identified in the left lower lobe. The homogeneous radioactive uptake following early and delayed imaging exhibited a SUV$_\text{max}$ of 6.0 and 6.9, respectively. The SUV$_\text{max}$ obtained from the delayed imaging exhibited a 15% increase compared with the early imaging. A heterogeneous elevated tracer uptake in the left upper lobe was observed in the other patient. In total, two nodule-like radioactive foci were identified within this lesion (Fig. 4C). The nodules exhibited an early SUV$_\text{max}$ of 5.4 and a delayed SUV$_\text{max}$ of 5.9, an increase of 9%. The PET/CT imaging characteristics are presented in Table III.

*Bone scan findings.* The patients that underwent SPECT were initially suspected of having lung cancer prior to the
surgery, which was determined by the absence of bone metastases. Of the four patients, two demonstrated no abnormal whole-body bone tracer uptake. Overall, one patient demonstrated a mildly increased tracer uptake, with a bilateral linear distribution along the cortex of the femurs, which was suggestive of atypical hypertrophic pulmonary osteoarthropathy (HPO) (Fig. 3E). The other patient possessed three foci that were located in the ribs, which were considered to demonstrate non-specific uptake in combination with the corresponding CT images.

Pathology and immunohistochemistry. Microscopic analysis revealed that the tumors were composed of bundles of spindle cells, including myofibroblasts and fibroblasts, arranged in a fascicular or storiform manner, and surrounded by chronic inflammatory cell infiltration (Fig. 4D). These inflammatory

---

Table I. Clinical data of 10 cases of pulmonary inflammatory myofibroblastic tumor.

| Patient | Gender | Age, years | Clinical symptoms | Medical history | Surgical management |
|---------|--------|------------|-------------------|----------------|-------------------|
| 1       | M      | 54         | Cough, expectoration, chest pain | Smoking, hypertension | Wedge resection |
| 2       | M      | 62         | Cough, expectoration, hemoptysis | Bronchiectasis, smoking | Lobectomy |
| 3       | M      | 56         | None              | None            | Lobectomy |
| 4       | M      | 56         | Cough, expectoration, hemoptysis | Smoking         | Lobectomy |
| 5       | F      | 54         | None              | Systemic lupus erythematosus | Lobectomy |
| 6       | F      | 65         | Cough              | Hypertension    | Lobectomy |
| 7       | M      | 58         | Chest pain        | Hypertension    | Lobectomy |
| 8       | M      | 49         | Cough, fever, chest pain | Smoking        | Percutaneous biopsy |
| 9       | M      | 41         | Back pain, fever  | Smoking        | Percutaneous biopsy |
| 10      | M      | 59         | Cough, expectoration, fever | Smoking      | Lobectomy |

M, male; F, female.

Table II. Computed tomography findings of eight cases of pulmonary inflammatory myofibroblastic tumor.

| Patient | Location | Size, mm | Margin     | Shape     | AP NCE | VP NCE | Others                                 |
|---------|----------|----------|------------|-----------|--------|--------|----------------------------------------|
| 1       | RLL, PP, SP | 44       | Well-defined | Oval     | 37.7   | 34.0   | Calcification, necrosis, necrosis, cavity |
| 2       | LLL, PP   | 34       | Ill-defined | Round    | 12.0   | 30.4   | Calcification, cavity, air bronchogram |
| 3       | RLL, PP, SP | 43      | Ill-defined | Irregular | 79.1   | 48.0   | Cavity, necrosis, air bronchogram |
| 4       | RUL, PP, SP | 38      | Ill-defined | Irregular | 44.2   | 57.9   | Necrosis, air bronchogram |
| 5       | RLL, PP   | 32       | Ill-defined | Irregular | 32.5   | 47.0   | Necrosis, air bronchogram |
| 6       | RUL, PP   | 30       | Ill-defined | Irregular | 25.3   | 47.8   | Necrosis, air bronchogram |
| 7       | RLL, PP   | 5        | Well-defined | Round   | NA     | NA     | Necrosis, obstructive pneumonia |
| 8       | RUL, CP   | 26       | Well-defined | Oval    | NA     | NA     | Necrosis, obstructive pneumonia |

RLL, right lower lobe; LLL, left lower lobe; RUL, right upper lobe; CP, central parenchyma; PP, peripheral parenchyma; SP, Sub-pleural; NCE, net contrast enhancement; AP, arterial phase; VP, venous phase; NA, not available.
cells were primarily composed of plasma cells, lymphocytes and granulocytes. Specimens obtained from the five patients were subjected to immunohistochemical examination. Positive staining for smooth muscle actin (Fig. 4E) was identified in all five cases, vimentin (Fig. 4F) in two cases, and cluster of differentiation (CD)68, CD34, CD20 and CD3 in one case.

**Table III.** $^{18}$F-fluorodeoxyglucose positron emission tomography/computed tomography findings of two cases of pulmonary inflammatory myofibroblastic tumor.

| Pt. No. | Location    | Size, mm | Margin    | Shape      | Others                 | UP                  | EI SUV$_{max}$ | DI SUV$_{max}$ |
|---------|-------------|----------|-----------|------------|------------------------|---------------------|----------------|----------------|
| 9       | LLL, PP, SP | 52       | Well-defined | Oval      | Air bronchogram         | Homogeneous          | 6.0            | 6.9            |
| 10      | LUL, PP, SP | 57       | Ill-defined | Irregular  | Calcification, air bronchogram | Heterogeneous        | 5.4            | 5.9            |

Pt, patient; No, number; LLL, left lower lobe; LUL, left upper lobe; PP, peripheral parenchyma; SP, sub-pleural; UP, uptake pattern; EI, early imaging; DI, delayed imaging; SUV$_{max}$, maximal standard uptake value.

Figure 1. Plain chest computed tomography (CT) of a 54-year-old male with a pulmonary inflammatory myofibroblastic tumor. (A) Lung window setting and (B) mediastinum window setting revealing a well-defined, sub-pleural mass in the peripheral parenchyma of the right lower lobe. Contrast-enhanced CT images of the sagittal section in (C) the arterial phase and (D) the venous phase revealing high contrast enhancement in the solid portion of the mass, associated with the necrotic region.

Figure 2. Plain chest computed tomography (CT) of a 58-year-old male with a pulmonary inflammatory myofibroblastic tumor. (A) Lung window setting revealing a small nodule with a maximum diameter of 5 mm located in the peripheral parenchyma of the right lower lobe. Due to its small size, contrast-enhanced CT images in (B) the arterial phase and (C) the venous phase were unable to reveal the degree of contrast enhancement of the nodule.
Discussion

PIMT is extremely uncommon. Overall, it is reported that ~40% of all cases occur in adults >40 years old (15) who are more likely to be affected by lung cancers. For this reason, a considerable number of PIMTs occurring in this age group are misdiagnosed as lung cancer prior to a biopsy or surgical resection (15,16). In the present study, which included ten patients >40 years old with PIMT, eight were originally suspected of having lung cancer prior to a wedge resection or lobectomy. In general, PIMT affects males and females equally (5,7,16,17). However, there was a significant male predilection (8/10) in the present study, which could be attributed to the older age group included. Patients with PIMT are usually asymptomatic, or present with non-specific symptoms, including coughing, hemoptysis, dyspnea, fever and chest pain (16,18,19). In the present study, two patients (2/10) were asymptomatic, and one pulmonary lesion was detected incidentally on a routine health check-up. Although the etiology of PIMT remains unknown, it has been hypothesized that pulmonary infection may contribute to the pathogenesis of the disorder, as prior pulmonary disease has only been reported in 30% of patients (14,16). The present study of 10 patients included only one patient with a previous pulmonary disease, but included six patients with a history of smoking, which indicates that smoking may be a factor that contributes to PIMT.

According to a study by Kakitsubata et al (16), no significant differences were identified between PIMT involving the left or right side. However, PIMT does exhibit a predilection for the lower lobes. In the present study, the right (4/10) and left lower lobes (2/10) were more frequently affected by PIMT compared with the right (3/10) and left (1/10) upper lobes. In addition, lesions located in the peripheral parenchyma (9/10) and sub-pleura (6/10) were observed more often, which indicates that PIMT may also have a predilection for these lung regions. It has been reported that the size of PIMT usually ranges between 10 and 150 mm (14,16,20). With the exception of one case, the size of the lesions in the present study corresponded with those previously reported. The exception in the present study had a maximum diameter of 5 mm. To the best of our knowledge, this is the smallest reported PIMT, which may aid in understanding the nature of PIMT.

At present, CT is the most widely used method for the detection and differentiation of pulmonary masses, including...
lung cancer, tuberculosis, inflammatory pseudotumors and PIMT (21). However, due to its rarity, major studies concerning CT delineations of PIMT are in the form of case studies. In total, two previous studies have included only ~10 cases (15,16). Although classic PIMT is defined as a slow-growing, solitary, round to oval-shaped and well-circumscribed mass in the peripheral regions of the lower lobes (16), CT manifestations of PIMT are generally diverse. A number of studies have reported that PIMTs present as ill-defined or irregular lesions (6,16,22-24). In addition, other CT findings, including calcification, cavity, necrosis, obstructive atelectasis and pneumonia have also been reported in several previous studies (8,9,15,16,18,20). According to the results of Kakitsubata et al (16), the incidence of calcification and cavities in cases of PIMT range between 4 and 17.5%, and 50 and 57%, respectively. The results of the present study are partly in agreement with those of previous studies. In total, four cases included in the present study were consistent with classic PIMT, and the other six cases existed as ill-defined or irregular masses. The presence of calcification and cavities was 30 (3/10) and 40% (4/10), respectively. However, necrosis and air bronchogram (60%; 6/10) were relatively frequent, which are factors rarely mentioned in previous studies.

The majority of PIMT cases reported in previous studies have demonstrated homogeneous or heterogeneous CT contrast enhancement (15,16,19,21). In addition, the degree of enhancement has varied between them. Calabrese et al (25) reported two cases of PIMT with mild increases in density following enhancement. Furthermore, Kim et al (15) assessed the degree of contrast enhancement in seven lesions and identified an increase in attenuation by 13-89 HU following contrast administration. Chen et al (19) described a patient with PIMT that demonstrated weak enhancement in the arterial phase. According to the study by Takayama et al (12), delayed enhancement was evident in two cases of PIMT. In this study, early-phase images with slight enhancement and delayed-phase images with heterogeneous enhancement were obtained 70 and 300 sec after the injection of the contrast medium, respectively. The presence of delayed enhancement has also been confirmed in certain studies reporting IMT occurring at other sites, including the heart, liver, kidney and the greater omentum (26-30). However, there have been certain cases of PIMT occurring in the absence of contrast enhancement, as reported by Kakitsubata et al (16) and Dhouib et al (14). The present study evaluated the degree of contrast enhancement in six patients with PIMT, which included the arterial and venous phases at 20 and 50 sec after the injection of the contrast agent, respectively. All lesions demonstrated moderate to high contrast enhancement in each phase, and four exhibited delayed enhancement.

To date, there have been a number of studies concerning $^{18}$F-FDG uptake in PIMT (5,6,9,14,19,25,31,32). These studies all demonstrated increased $^{18}$F-FDG uptake, with the SUV values ranging between 2.8 and 25. The present study included two cases of PIMT that were analyzed by $^{18}$F-FDG PET/CT, and exhibited elevated $^{18}$F-FDG uptake with SUV values above the normal range. Although $^{18}$F-FDG is known to accumulate in a number of malignancies, including lung cancer, it has also been observed to actively concentrate in certain benign pulmonary diseases, such as pneumonia, Wegener's granulomatosis, tuberculosis, fungal infections and abscesses (32). Overall, two cases in the present study were not identified as having lung cancer following PET/CT, which confirmed the presence of pulmonary unifocal lesions without metastatic disease. Furthermore, the two PIMT lesions underwent delayed PET/CT imaging, which had not been performed in previous case studies. In the two cases, the SUV$_{max}$ of the delayed imaging were higher than those of the initial imaging. A number of previous studies have revealed that dual time-point $^{18}$F-FDG PET or PET/CT
imaging may aid in distinguishing malignant from benign processes (33-37). Malignant diseases, including hepatocel-
lar carcinoma, pancreatic cancer, lung cancer and malignant lymphoma have demonstrated increased 18F-FDG accumu-
lation on delayed images compared with early images. However, there have been other studies that have identified a significant overlap in 18F-FDG uptake patterns between benign and malignant lesions, particularly for pulmonary lesions, and even on delayed time-point images (38-42). As revealed by the present study, an increased delayed imaging SUVmax of the lung cannot guarantee the presence of malignancy. These 18F-FDG PET/CT findings may aid in the diagnosis of PIMT, but further studies that include larger patient populations are required in order to expand these results.

The bone scan features of PIMT have not been depicted in previous studies. The present study included four patients who underwent SPECT for the detection of bone metastases. Although there were no definitive bone metastases detected, SPECT revealed atypical HPO in one PIMT case. HPO can occur secondary to various neoplastic and non-neoplastic diseases, including primary lung cancer, metastatic pulmonary disease and cystic fibrosis (43). The ‘tram-line’ or ‘double-stripe’ sign, which represents abnormal periskeletal bone formation, is the classic appearance of HPO upon bone scanning (43,44). With the exception of PIMT, CT did not identify any other pulmonary diseases in the patient with HPO in the present study. Based upon the chest CT findings, it was hypothesized that the HPO detected by SPECT was caused by the PIMT. To the best of our knowledge, this is the first study to demonstrate that PIMT can lead to HPO.

PIMT occurring in patients >40 years old is extremely rare and the symptoms often mimic those of lung cancer (13,19). Certain imaging features are relatively common in PIMT patients of this age group, such as being located in the lower lobe and peripheral parenchyma, necrosis, air bronchogram, moderate to high contrast enhancement or delayed enhance-
ment, increased 18F-FDG uptake with an elevated SUVmax upon delayed imaging, and the absence of definitive metastases. Although these imaging features remain non-specific for the distinction between PIMT and lung cancer, they may aid in enhancing the awareness of PIMT during the differential diag-
nosis of lung masses. The combination of imaging modalities, including CT, 18F-FDG PET/CT and SPECT bone scans, may aid in successfully diagnosing PIMT, determining the extent of the tumor and also managing the treatment.

References
1. Verbeke JI, Verbrerne AA, Den Hollander JC and Robben SG: Inflammatory myofibroblastic tumour of the lung manifesting as progressive atelectasis. Pediatr Radiol 29: 816-819, 1999.
2. Swain RS, Tihan T, Horvai AE, et al: Inflammatory myofibro-
blastic tumor of the central nervous system and its relationship to inflammatory pseudotumor. Hum Pathol 39: 410-419, 2008.
3. Chen ST and Lee JC: An inflammatory myofibroblastic tumor in liver with ALK and RANBP2 gene rearrangement: combination of distinct morphologic, immunohistochemical and genetic features. Hum Pathol 39: 1854-1858, 2008.
4. Butynski JE, D’Adamo DR, Hornick JL, et al: Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 363: 1727-1733, 2010.
5. Takeda S, Onishi Y, Kawamura T and Maeda H: Clinical spectrum of pulmonary inflammatory myofibroblastic tumor. Interact Cardiovasc Thorac Surg 7: 629-633, 2008.
6. Carillo C, Anile M, De Giacomo T and Venuta F: Bilateral simultaneous inflammatory myofibroblastic tumor of the lung with distant metastatic spread. Interact Cardiovasc Thorac Surg 13: 246-247, 2011.
7. Ezzine-Baccari S, Bacha D, Sassi S, et al: Inflammatory myofi-
broblastic tumor of the lung: a benign lesion with aggressive behavior. Gen Thorac Cardiovasc Surg 60: 531-533, 2012.
8. Sharma S, Sankhyan N, Kahlra V, et al: Inflammatory myofibro-
blastic tumor involving lung and brain in a 10-year-old boy: a case report. J Child Neurol 27: 1302-1306, 2009.
9. van den Heuvel DA, Keijzers RG, van Es HW, et al: Invasive inflammatory myofibroblastic tumor of the lung. J Thorac Oncol 4: 923-926, 2009.
10. Okiror L, Draaisma WA, Chinate C and Harrison-Phipps K: Large pulmonary inflammatory myofibroblastic tumour requiring extra-
pleural pneumonectomy and diaphragm resection. Gen Thorac Cardiovasc Surg 61: 163-165, 2013.
11. Kim SJ, Kim WS, Cheon JE, et al: Inflammatory myofibroblastic tumors of the abdomen as mimickers of malignancy: imaging features in nine children. AJR Am J Roentgenol 193: 1419-1424, 2009.
12. Takayama Y, Yabuchi H, Matsuo Y, et al: Computed tomographic and magnetic resonance features of inflammatory myofibroblastic tumor of the lung in children. Radiat Med 26: 613-617, 2008.
13. Sakurai H, Hasegawa T, Watanabe S, et al: Inflammatory myofi-
broblastic tumor of the lung. Eur J Cardiothorac Surg 25: 155-159, 2004.
14. Dhoob A, Barazzzone C, Reverdin A, et al: Inflammatory myofi-
broblastic tumor of the lung: a rare cause of atelectasis in children. Pediatr Radiol 43: 381-384, 2013.
15. Kim TS, Han J, Kim G, et al: Pulmonary inflammatory pseu-
dotumor (inflammatory myofibroblastic tumor): CT features with pathologic correlation. J Comput Assist Tomogr 29: 633-639, 2005.
16. Kakitsubata Y, Theodorou SJ, Theodorou DJ, et al: Myofibroblastic inflammatory tumor of the lung: CT findings with pathologic corre-
lation. Comput Med Imaging Graph 31: 607-613, 2007.
17. Ochs K, Hoksbr Schrey U and Schmid RA: Inflammatory myofibroblastic tumor of the lung in a five-year-old girl. Interact Cardiovasc Thorac Surg 10: 805-806, 2010.
18. Hammas N, Chibani L, Rami M, et al: A rare tumor of the lung: inflammatory myofibroblastic tumor. Diagn Pathol 7: 83, 2012.
19. Chen CK, Jan CI, Tsai JS, et al: Inflammatory myofibroblastic tumor of the lung-a case report. J Cardiothorac Surg 5: 55, 2010.
20. Cassivi SD and Wylam ME: Pulmonary inflammatory myofi-
broblastic tumor associated with histoplasmosis. Interact Cardiovasc Thorac Surg 5: 514-516, 2007.
21. Naïdich DP, Bankier AA, MacMahon H, et al: Recommendations for the management of subsolid pulmonary nodules detected at CT: a statement from the Fleischner Society. Radiology 266: 304-317, 2013.
22. Lee MH, Lee HB, Lee YC, et al: Bilateral multiple inflammatory myofibroblastic tumors of the lung successfully treated with corti-
costeroids. Lung 189: 433-435, 2011.
23. Schaeffer CJ, Miniai OA, Sharma N, et al: Inflammatory myofi-
broblastic tumor of the lung: recurrence after steroid treatment. J Thorac Imaging 23: 191-193, 2008.
24. Nakamura H, Kawasaki N, Taguchi M, et al: Pulmonary inflammatory myofibroblastic tumor resected by video-assisted thoracoscopic surgery: Report of a case. Surg Today 37: 137-140, 2007.
25. Calabrese F, Zain A, Brambilla E, et al: Pulmonary inflammatory myofibroblastic tumor with unexplained octreoscan uptake: two reports. Eur Respir J 35: 448-450, 2010.
26. Wen L, Sun QR, Diao XW, et al: Renal inflammatory myofibroblastic tumor with multiple calcifications. Clin Radioi 67: 188-191, 2012.
27. Apfel S, Gervaise A, Fairaise A, et al: Abdominal inflammatory myofibroblastic tumor. Diagn Interv Imaging 93: 410-412, 2012.
28. Hoey ET, Ganeshe V, Gopalan D and Screeaton NF: Cardiac inflamm-
atory myofibroblastic tumor: evaluation with dual-source CT. J Cardiovasc Comput Tomogr 3: 114-116, 2009.
29. See TC, Davies SE, Appleton DS and Ng CS: CT and angio-
graphic features of hepatic inflammatory myofibroblastic tumour. Clin Radiol 60: 715-722, 2005.
30. Yu JS, Park C, Kim JH, et al: Inflammatory myofibroblastic tumors in the liver: MRI of two immunohistochemically-verified cases. J Magn Reson Imaging 26: 418-421, 2007.
31. Okiror L, Draaisma WA, Chinate C, et al: Large pulmonary inflammatory myofibroblastic tumour requiring extrapleural pneumonectomy and diaphragm resection. Gen Thorac Cardiovasc Surg 61: 163-165, 2013.
32. Howman-Giles R, London K, McCowage G, et al: Pulmonary inflammatory myofibroblastic tumor after Hodgkin's lymphoma and application of PET imaging. Pediatr Surg Int 24: 947-951, 2008.
33. Xiu Y, Bhutani C, Dhurairaj T, et al: Dual-time point FDG PET imaging in the evaluation of pulmonary nodules with minimally increased metabolic activity. Clin Nucl Med 32: 101-105, 2007.
34. Schillaci O, Travascio L, Bolacchi F, et al: Accuracy of early and delayed FDG PET-CT and of contrast-enhanced CT in the evaluation of lung nodules: a preliminary study on 30 patients. Radiol Med 114: 890-906, 2009.
35. Shinya T, Fujii S, Asakura S, et al: Dual-time-point F-18 FDG PET/CT for evaluation in patients with malignant lymphoma. Ann Nucl Med 26: 616-621, 2012.
36. Nishiyama Y, Yamamoto Y, Monden T, et al: Evaluation of delayed additional FDG PET imaging in patients with pancreatic tumour. Nucl Med Commun 26: 895-901, 2005.
37. Lin WY, Tsai SC and Hung GU: Value of delayed 18F-FDG-PET imaging in the detection of hepatocellular carcinoma. Nucl Med Commun 26: 315-321, 2005.
38. Chen CJ, Lee BF, Yao WJ, et al: Dual-phase 18F-FDG PET in the diagnosis of pulmonary nodules with an initial standard uptake value less than 2.5. AJR Am J Roentgenol 191: 475-479, 2008.
39. Laffon E, de Clermont H, Begueret H, et al: Assessment of dual-time-point 18F-FDG-PET imaging for pulmonary lesions. Nucl Med Commun 30: 455-461, 2009.
40. Umeda Y, Demura Y, Morikawa M, et al: Prognostic value of dual-time-point 18F-fluorodeoxyglucose positron emission tomography in patients with pulmonary sarcoidosis. Respirology 16: 713-720, 2011.
41. Zheng Z, Pan Y, Guo F, et al: Multimodality FDG PET/CT appearance of pulmonary tuberculoma mimicking lung cancer and pathologic correlation in a tuberculosis-endemic country. South Med J 104: 440-445, 2011.
42. Cheng G, Torigian DA, Zhuang H, et al: When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET? Eur J Nucl Med Mol Imaging 40: 779-787, 2013.
43. Narla VV, Rajagopalan MS, Kanderi T and Muthukrishnan A: Atypical presentation of hypertrophic pulmonary osteoarthropathy on Tc-99 m MDP bone scintigraphy. Clin Nucl Med 33: 702-704, 2008.
44. Russo RR, Lee A, Mansberg R and Emmett L: Hypertrophic pulmonary osteoarthropathy demonstrated on SPECT/CT. Clin Nucl Med 34: 628-631, 2009.